Azasite

Urethritis, Chancroid, Tonsillitis + 34 more

Treatment

32 FDA approvals

20 Active Studies for Azasite

What is Azasite

Azithromycin

The Generic name of this drug

Treatment Summary

Azithromycin is an antibiotic used to treat bacterial infections, such as respiratory, enteric, and genitourinary infections. It belongs to the azalide class of macrolides, which have a 15-membered ring and a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring. This prevents its metabolism, making it more effective than other macrolide antibiotics. In 2020, a study was conducted to investigate the use of azithromycin in combination with hydroxychloroquine to treat COVID-19, with positive results. However

Zithromax

is the brand name

image of different drug pills on a surface

Azasite Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zithromax

Azithromycin

1994

541

Approved as Treatment by the FDA

Azithromycin, otherwise called Zithromax, is approved by the FDA for 32 uses including Bacterial Sinusitis and Sinusitis .

Bacterial Sinusitis

Sinusitis

Haemophilus Influenzae Infections

Genus Chlamydia

patients appropriate for oral therapy

Tonsillitis bacterial

genital ulcers caused by haemophilus ducreyi infection

Acute Otitis Media (AOM)

Streptococcus pyogenes

Streptococcal Pharyngitis

Tonsillitis streptococcal

unable to prescribe first line therapy for streptococcus pyogenes tonsillitis

Tonsillitis

Haemophilus ducreyi infection

Moraxella Catarrhalis Infection

Community Acquired Pneumonia (CAP)

Moraxella catarrhalis

ABDIC protocol

Adults

Streptococcus Pneumoniae Infections

Adult Patients

Genital Ulcer Disease (GUD)

Communicable Diseases

Staphylococcus (S.) Aureus Infection

Pneumococcal Infections

Pneumonia, Mycoplasma

Tonsillitis

Pediatric Patients

Otitis

Sore Throat

Streptococcus pyogenes

Streptococcus Agalactiae Infection

Effectiveness

How Azasite Affects Patients

Macrolides are antibiotics that work by stopping the bacteria from making proteins, which helps to treat bacterial infections. Azithromycin has been used to treat chronic inflammatory respiratory diseases, as it also helps to regulate the immune system.

How Azasite works in the body

Azithromycin is an antibiotic used to treat bacterial infections. It works by preventing bacteria from producing proteins they need to survive. Specifically, it binds to the ribosome and stops it from being able to make proteins. This makes it effective against a wide range of bacteria. Azithromycin is also very stable at a low pH, meaning it stays in the body longer and can build up to higher levels in tissue than other antibiotics.

When to interrupt dosage

The prescribed measure of Azasite is contingent upon the recognized sickness, including Streptococcus Agalactiae Infection, Chlamydia trachomatis and Genus Chlamydia. The magnitude of dosage is contingent upon the technique of delivery, as detailed in the table beneath.

Condition

Dosage

Administration

Streptococcus Agalactiae Infection

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Urethritis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Chancroid

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Conjunctivitis, Bacterial

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Communicable Diseases

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Otitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Tonsillitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Chlamydia trachomatis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Genus Chlamydia

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Genital Ulcer Disease (GUD)

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Haemophilus ducreyi infection

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Streptococcus pyogenes

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Moraxella catarrhalis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Uterine Cervicitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Sinusitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Adult Patients

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Tonsillitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Bacterial conjunctivitis

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Pneumonia, Mycoplasma

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Communicable Diseases

, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Powder, for solution - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release - Oral, Granule, for suspension, extended release, Solution - Ophthalmic, Solution, For suspension, For suspension - Oral, Powder, for suspension - Parenteral, Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Warnings

Azasite Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

Jaundice, Obstructive

Do Not Combine

prior azithromycin use

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Azithromycin may interact with Pulse Frequency

There are 20 known major drug interactions with Azasite.

Common Azasite Drug Interactions

Drug Name

Risk Level

Description

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Asenapine.

Astemizole

Major

The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Astemizole.

Azasite Toxicity & Overdose Risk

Azithromycin has been found to be toxic to rats when taken orally at a dose of >2000mg/kg. Possible side effects include irregular heartbeats, hearing loss, decreased effectiveness of the drug, and rare cases of liver or kidney damage. Pregnant women should only take azithromycin if absolutely necessary, as the effects on the fetus are unknown. Nursing mothers should take caution when taking azithromycin, as it is not known if the drug is excreted in human milk. No long-term studies have been done to determine if the drug is carcinogenic or has any effects on fertility

image of a doctor in a lab doing drug, clinical research

Azasite Novel Uses: Which Conditions Have a Clinical Trial Featuring Azasite?

Currently, 9 active clinical trials are investigating the potential of Azasite to treat Moraxella Catarrhalis Infection, Staphylococcus (S.) Aureus Infection and other Communicable Diseases.

Condition

Clinical Trials

Trial Phases

Sinusitis

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Staphylococcus (S.) Aureus Infection

2 Actively Recruiting

Phase 4, Phase 1

Conjunctivitis, Bacterial

0 Actively Recruiting

Streptococcus pyogenes

0 Actively Recruiting

Moraxella catarrhalis

0 Actively Recruiting

Streptococcus Agalactiae Infection

0 Actively Recruiting

Haemophilus Influenzae Infections

0 Actively Recruiting

Uterine Cervicitis

0 Actively Recruiting

Genital Ulcer Disease (GUD)

0 Actively Recruiting

unable to prescribe first line therapy for streptococcus pyogenes tonsillitis

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Streptococcus pyogenes

0 Actively Recruiting

Diarrhea

0 Actively Recruiting

Tonsillitis

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Pneumococcal Infections

0 Actively Recruiting

Pediatric Patients

0 Actively Recruiting

Adult Patients

0 Actively Recruiting

Chancroid

0 Actively Recruiting

Azasite Reviews: What are patients saying about Azasite?

1.7

Patient Review

1/10/2013

Azasite for Pink Eye from Bacterial Infection

The packaging is really inconvenient, and you don't get enough drops to finish the treatment.

1.3

Patient Review

2/20/2012

Azasite for Pink Eye from Bacterial Infection

Terrible. It was very expensive and hard to dispense and burns like hell. The other opthalmic solutions I've used for pink eye have been completely painless and effective. My doc told me this was better. Not so, my eyes still hurt 1 hour after putting these slimy drops in.

1.3

Patient Review

4/10/2012

Azasite for Pink Eye from Bacterial Infection

Not only is this medication overpriced, but one container does not have enough product to finish the recommended course of treatment. In addition, this drug did nothing to ease my symptoms.

1

Patient Review

2/13/2012

Azasite for Pink Eye from Bacterial Infection

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about azasite

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is AzaSite still available?

"There is no version of Azasite that is equivalent to the therapeutic version available in the United States. These online pharmacies selling the generic version may be counterfeit and potentially unsafe."

Answered by AI

What kind of drug is AzaSite?

"Azasite is a semi-synthetic macrolide antibiotic used for the bacterial conjunctivitis."

Answered by AI

What is AzaSite used to treat?

"It will not work for other types of eye infections.

This medication is used to treat certain eye infections which are caused by bacteria. It works by stopping the growth of bacteria. This medication will not work for other types of eye infections."

Answered by AI

Is there a generic for AzaSite eye drops?

"There is no generic form of the antibiotic AzaSite currently available, though there are alternative brands that may be more affordable depending on your insurance coverage. Talk to your doctor about other options that may be available to you."

Answered by AI

Clinical Trials for Azasite

Image of Grady Memorial Hospital in Atlanta, United States.

Point-of-care Testing for Sexually Transmitted Infections

Any Age
Female
Atlanta, GA

The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women. It will also learn about the feasibility, acceptability, and cost-effectiveness of implementing POCTs in a large safety-net hospital setting. The main questions it aims to answer are: * Do POCTs reduce delays in STI treatment compared with standard laboratory-based testing? * What barriers, facilitators, and processes affect POCT implementation in prenatal and obstetric care? * What are the costs and cost-effectiveness of POCTs compared with standard testing? Participants will: * Complete a baseline survey and receive either POCTs (fingerstick blood draw or vaginal swab) or standard laboratory STI testing. * If diagnosed with an STI, complete a follow-up survey approximately one month later. * Stakeholders (providers, hospital leadership, and public health officials) will complete interviews to inform implementation strategies.

Waitlist Available
Has No Placebo

Grady Memorial Hospital

Kristin Wall, PhD

Image of Centre for Urban Innovation (CUI-109), School of Nutrition, Toronto Metropolitan University in Toronto, Canada.

White Potatoes for Glycemic Responses

18 - 65
All Sexes
Toronto, Canada

The purpose of this study is to evaluate the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. The investigators hypothesize that white potatoes will modulate glycemic response, enhance satiety, and mitigate subsequent meal consumption and overall food intake when compared with meals containing low glycemic carbohydrates. Furthermore, they anticipate that the timing of white potato consumption will yield differential effects, with breakfast consumption exerting a more pronounced impact on satiety and subsequent food intake reduction compared to dinner consumption.

Recruiting
Has No Placebo

Centre for Urban Innovation (CUI-109), School of Nutrition, Toronto Metropolitan University

Have you considered Azasite clinical trials?

We made a collection of clinical trials featuring Azasite, we think they might fit your search criteria.
Go to Trials
Image of Washington University in St. Louis in St Louis, United States.

Adapted HARP for Falls Prevention

45 - 64
All Sexes
St Louis, MO

The Home Hazard Removal Program (HARP) is an effective fall prevention intervention program which targets home hazard identification/removal. In this study the investigators will examine the effectiveness and implementation potential of HARP, adapted for PwD. Investigators will conduct a pilot randomized control trial (RCT) to test the implementation, cost, and preliminary efficacy of an adapted version of HARP for community-dwelling PwD. The single-blinded feasibility RCT will randomize 40 participants to treatment (adapted HARP) and 40 to a waitlist control group. Data on specific types of fall hazards and resulting home modifications as well as falls and fall-related injuries (collected monthly over 12 months) and fear of falling (collected at baseline and 12 months) will inform the preliminary efficacy of adapted HARP among PwD. To ensure usefulness, relevance, and broad dissemination of findings, the investigators will adopt a "designing for implementation and dissemination" approach. The RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework will guide intervention adaptation, trial design, and future implementation. The Practical Robust Implementation and Sustainability Model (PRISM) guides study development by identifying multi-level contextual factors hypothesized to affect the RE-AIM outcomes.

Recruiting
Has No Placebo

Washington University in St. Louis

Susan L Stark, PhD

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Image of USC Voice Center in Arcadia, United States.

Voice Therapy for Age-Related Voice Change

18+
All Sexes
Arcadia, CA

This study compares how well voice therapy works when delivered in-person versus through telehealth for older adults with age-related voice problems. Researchers are testing whether Phonation Resistance Training Exercises (PhoRTE®) can be just as effective when delivered remotely as when done face-to-face, which could make treatment more accessible and affordable for seniors. The two primary hypotheses are: 1. Does voice therapy (called PhoRTE®) work as well through video calls as it does face-to-face? 2. Can online therapy be a more accessible way for older adults to get help for their voice problems? Adults aged 55 or older with voice changes and an applicable diagnosis will be randomly assigned to receive either in-person or telehealth therapy, consisting of four 45-minute sessions. After treatment, researchers will measure improvements through: * Changes in voice function * Patient reports about their voice * Scientific measurements of voice quality * Patient satisfaction with treatment * Impact on quality of life The results will help determine if telehealth can be a good alternative to in-person voice therapy, especially important as telehealth coverage may be changing.

Waitlist Available
Has No Placebo

USC Voice Center (+3 Sites)

Aaron Rothbart, PhD

Have you considered Azasite clinical trials?

We made a collection of clinical trials featuring Azasite, we think they might fit your search criteria.
Go to Trials
Image of Loma Linda University Medical Center Troesh Medical Campus in Loma Linda, United States.

Endotracheal Suctioning for Procedural Pain

18+
All Sexes
Loma Linda, CA

The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress. The main questions this study aims to answer are: Does ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress. Participants will: Have pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning. Provide demographic information (like age, gender, and diagnosis) from medical records. This research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.

Recruiting
Has No Placebo

Loma Linda University Medical Center Troesh Medical Campus

Elizabeth Johnston Taylor, PhD, FAAN

Have you considered Azasite clinical trials?

We made a collection of clinical trials featuring Azasite, we think they might fit your search criteria.
Go to Trials